ir.bioxceltherapeutics.comInvestor Relations :: BioXcel Therapeutics, Inc. (BTAI)

Overview Management Team Board of Directors Strategic Advisors Product Pipeline Overview Expanded Access News & Media Press Releases Publications Events Media Investors Investor Relations Overview News / Events Overview Press Releases Press Coverage IR Calendar Email Alerts Company Info Overview Presentations Management Team Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Overview Quote Charts Historical Data Analyst Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Business Development Careers Overview Job Openings Contact Investor Relations Investors Investors Overview News / Events Overview Press Releases Press Coverage IR Calendar Email Alerts Company Info Overview Presentations Management Team Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Overview Quote Charts Historical Data Analyst Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents IR Tools Email Alerts Tear Sheet Contacts RSS News Feed Latest News BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation Feb 25, 2021 View All News Latest Financial Results Q3 2020 Quarter Ended Sep 30, 2020 Earnings Release PDF HTML Audio Earnings Webcast 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Report Fiscal Year Ended Dec 31, 2019 View Annual Report Sign up for Email Alerts Email Sign Up First Name Last Name Email Address Contact Type: Individual Investor Analyst Broker/Investment Advisor Portfolio Manager Banker/Financing Source Press/Media Consultant Employee Customer/Client Student Other Sign me up for: Press Releases Annual & Quarterly Reports Current Reports Insider Transactions Proxy Information All Filings Sign Up Stock Information Company Overview BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. BioXcel Therapeutics Presentation – J.P. Morgan Healthcare Conference Download BioXcel Therapeutics Presentation – J.P. Morgan Healthcare Conference Leadership Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success. View Management Team View Board of Directors Investor Contact Information Company BioXcel Therapeutics, Inc. 555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States T: 475-238-6837 info@bioxceltherapeutics.com Investor Relations Solebury Trout John Graziano T: 1.646.378.2942 jgraziano@troutgroup.com Transfer Agent American Stock Transfer and Trust © 2021 BioXcel Therapeutics, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Market Data copyright © 2021 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use...